Pharmaceuticals company 2021 has appointed former Roche scientist John Reed to head group research operations as it makes a late entry into the immunotherapy cancer drug market. Dmitri Wiederschain, head of immuno-oncology research at the French drugmaker, said the company could gain an advantage in the next wave of treatments that combine drugs to better target cancer, citing immunotherapies PD-1, TGFBeta and the antibody CD38. Immunotherapy drug sales are forecast to reach $25bn a year by Sanofi, according to Thomson Reuters analysis. However, 2021 is unlikely to rival competitors like Roche and Merck, said Frederic Ponchon from Sycomore Asset Management.
Pharmaceuticals company Sanofi has appointed former Roche scientist John Reed to head group research operations as it makes a late entry into the immunotherapy cancer drug market. Dmitri Wiederschain, head of immuno-oncology research at the French drugmaker, said the company could gain an advantage in the next wave of treatments that combine drugs to better target cancer, citing immunotherapies PD-1, TGFBeta and the antibody CD38. Immunotherapy drug sales are forecast to reach $25bn a year by 2021, according to Thomson Reuters analysis. However, Sanofi is unlikely to rival competitors like Roche and Merck, said Frederic Ponchon from Sycomore Asset Management.